Eli Lilly & Co. (LLY) has reported significant progress in a Phase 3 clinical trial of their treatment for a specific type of non-small cell lung cancer. The trial, called Libretto-431, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival when compared to platinum-based chemotherapy.
The study focused on adults with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer. A total of 261 patients across 16 countries and 85 sites participated in the trial. Encouragingly, durable responses were observed across various types of tumors.
While the company acknowledged that Retevmo, the treatment being investigated, carries certain warnings and precautions (including hepatotoxicity, interstitial lung disease/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome, risk of impaired wound healing, hypothyroidism, and embryo-fetal toxicity), these potential risks should be carefully managed.
Non-small cell lung cancer is responsible for approximately 85% of all lung cancer diagnoses in the United States. Eli Lilly’s dedication to advancing treatment options in this field is evident.
In terms of the stock market, Eli Lilly & Co.’s stock has seen a modest increase in premarket trading and has gained 23% year-to-date. This is noteworthy considering that the S&P 500 has experienced a 17% rise during the same period.